SOURCE: NEMUS Bioscience

Nemus Bioscience

July 07, 2015 08:30 ET

NEMUS Announces Research Agreement With the University of Mississippi to Develop Proprietary Cannabidiol (CBD) Molecules

COSTA MESA, CA--(Marketwired - July 07, 2015) - NEMUS Bioscience, Inc. (OTCQB: NMUS) announced the signing of a research agreement with the University of Mississippi (UM) to study and conduct research and development on cannabidiol (CBD) containing formulations.

"CBD has shown evidence of therapeutic activity in a variety of diseases, particularly those involving the nervous system, immune reactivity and inflammation. Determining effective means of administering this molecule was a primary goal for NEMUS this year and we are excited to commence further development with our partner, the University of Mississippi," reports John Hollister, CEO of NEMUS.

"When working with cannabinoids, it is important to develop therapies that enhance bioavailability in a predictable and safe way. This is a central tenet of our cannabinoid research program and underlies our objectives in the development of proprietary forms of CBD that could have multiple candidate routes of administration based on the disease state of the patient," stated Brian Murphy, MD, Chief Medical Officer of NEMUS. "Our next steps will be to prioritize medical indications where CBD will be effective using technology platforms developed by our partners at UM."

"The university is looking forward to advancing new formulations of CBD to meet serious medical conditions where non-psychotropic cannabinoids can play a significant role," added Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research at UM and a leading global expert on cannabinoid chemistry. "The impact CBD has on multiple physiologic systems makes it an attractive candidate for medicinal development," commented Dr. Soumyajit Majumdar, Associate Professor of Pharmaceutics and Drug Delivery and Associate Dean for Research in the School of Pharmacy at the university.

"NEMUS is continuing our glaucoma and MRSA therapeutic development programs and is looking forward to incorporating CBD into our product portfolio where appropriate," commented Mr. Hollister.

NEMUS Bioscience and the University of Mississippi entered into a research and in-licensing collaboration agreement in 2014.

ABOUT NEMUS BIOSCIENCE, INC.
The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit www.nemusbioscience.com.

FORWARD LOOKING STATEMENTS

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable" "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.

Contact Information